•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Fosamax
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and time to contact you:

Date of birth (mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Were you diagnosed with Osteonecrosis of the Jawbone (ONJ)?


Please describe ONJ symptoms and treatment:

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


AddThis Social Bookmark Button

Fosamax Linked to Severe Musculoskeletal Pain and Osteonecrosis of the Jaw Injury - Free Lawsuit Case Review by a Fosamax Side Effects Injury Lawyer

Keywords: Fosamax | Side Effects | Lawyer | Injury | Lawsuit | Victims | Pain | Attorney | ONJ

Fosamax, a popular osteoporosis drug, has been linked to severe musculoskeletal pain (pain of the joints, muscles, and/or bones), as well as a serious bone disease called Osteonecrosis of the Jaw (ONJ), also known as "dead jaw" and "fossy jaw".  An article on the association between Fosamax and ONJ was first  published in the Journal of Oral and Maxillofacial Surgeons, which prompted the US Food and Drug Administration (FDA) to review the safety of Fosamax and other drugs in its class (bisphosphonate drugs). On January 31, 2005, Merck, the manufacturer of Fosamax, received a request for data from the FDA to update the label for Fosamax to include labeling for the jawbone tissue disease. The revised label was not made available until July 2005.

On January 7, 2008, the FDA  warned that Fosamax had been linked to severe and sometimes incapacitating bone, joint, and muscle (musculoskeletal) pain.  The agency advised doctors and patients to be aware of this side effect, and to discontinue Fosamax use should it occur.

If you have used Fosamax and have suffered any sever muscle, joint or bone pain, or have experienced jaw injury or disease, contact Parker & Waichman, LLP to have a Fosamax lawyer review your case. Please complete the contact form on the right of this page to have your Fosamax side effects case review today. Alternatively, call 1-800-LAW-INFO (1-800-529-4636) to speak to someone immediately.

About Fosamax
Fosamax (Generic: Alendronate Sodium), manufactured by Merck, gained FDA approval in 1995.  Fosamax Plus D (Generic: Alendronate Sodium Cholecalciferol) contains Vitamin D.  Fosamax is prescribed to treat osteoporosis and Paget's disease. Fosamax is a type of drug known as a bisphosphonate.  Individuals using Fosamax or other bisphosphonate medications should attempt to steer clear of tooth extractions and other major dental work while on the drugs.

Fosamax is a Bisphosphonate
Bisphosphonate drugs are commonly used in tablet form to prevent and treat osteoporosis in post-menopausal women. Stronger forms of bisphosphonate drugs are used in the management of advanced cancers that have metastasized to the bone, where the disease often causes bone pain and possibly even fractures. Several cancers can involve or metastasize to the bone, including lung cancer, breast cancer, prostate cancer, multiple myeloma, and others. When bisphosphonates are given in cancer chemotherapy, the drugs are given intravenously in higher doses and usually for longer periods of time.

About Osteonecrosis of the Jaw (ONJ)
Osteonecrosis of the Jaw (ONJ) is a condition in which the bone tissue in the jaw fails to heal after minor trauma such as a tooth extraction, causing the bone to be exposed. The exposure can eventually lead to infection and fracture and may require long-term antibiotic therapy or surgery to remove the dying bone tissue. Experts say that prevention and early treatment of patients using bisphosphonates such as Fosamax is extremely important in preserving the jawbone. Signs and symptoms of ONJ may include:  jaw pain, swelling of the gums, loose teeth, drainage, exposed jaw bone, numbness, or a feeling of heaviness in the jaw.  Loss of blood supply to the jaw preceeds the development of ONJ.  Fosamax reduces the activity of the cells that cause bone loss, which is supposed to decrease the rapid rate of bone loss in women after menopause.  However, this exact mechanism may be what causes osteonecrosis of the jawbone.

Fosamax and Severe Musculoskeletal Pain
According to the 2008 FDA Fosamax health alert, the severe musculoskeletal pain associated with Fosamax can occur within days, months, or years after starting treatment with the drug.  While some patients have experienced complete relief of symptoms after discontinuing Fosamax, others have reported that the pain continued.  The risk factors for and incidence of severe musculoskeletal pain associated with Fosamax are unknown. 

Although severe musculoskeletal pain was already included in the prescribing information for Fosamax, the FDA said that the association between Fosamax and severe musculoskeletal pain could be overlooked by healthcare professionals, resulting in delayed   diagnosis, prolonged pain and impairment, and the need for treatment with analgesics. The FDA has recommended that healthcare professionals be aware that the use of Fosamax could be responsible for severe musculoskeletal pain in patients who present with this symptom.   If patients on Fosamax do experience this severe musculoskeletal pain, the FDA advised that  their doctors  consider temporary or permanent discontinuation of the drug.

Free Fosamax Lawsuit Consultation
If you or a loved one took Fosamax and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call 1-800-LAW-INFO (1-800-529-4636).
FosamaxRSS Feed

Second Fosamax Test Case an $8 Million Win for Plaintiff

Jun 28, 2010 | Parker Waichman Alonso LLP
A New York jury has ordered Merck & Co. to pay $8 million to a former Fosamax user who claimed she developed osteonecrosis of the jaw (ONJ), or dead jaw syndrome, from taking the osteoporosis drug. The award was $3 million more than plaintiff Shirley Boles had asked for in her lawsuit. Merck has already said it plans to appeal the verdict, and has called the damage award “excessive”. Fosamax is one of a number of drugs used to treat osteoporosis known as bisphosphonates. Other...

Fosamax, Other Osteoporosis Drugs, Raise Concerns Over Femur Fractures

Mar 11, 2010 | Parker Waichman Alonso LLP
There are more concerns today that  Fosamax, Actonel, Boniva, and Reclast, a class of drugs known as oral bisphosphonates that are used to prevent and treat osteoporosis in post-menopausal women, could be causing a specific type of femur fracture in some patients.  Yesterday, the Food & Drug Administration (FDA) said it would be taking a look at the issue. According to a notice posted on the FDA’s Web site, in June 2008 the agency requested information from all...

Judge Rules not to Dismiss 24 Fosamax Lawsuits

Sep 10, 2009 | Parker Waichman Alonso LLP
Twenty-four Fosamax lawsuits filed by people who took the drug for less than  three years will not be dismissed.   In a ruling released yesterday, U.S. District Judge John Keenan also said that testimony from two plaintiffs' experts is admissible at trial.Fosamax is one of a number of drugs used to treat osteoporosis known as bisphosphonates. Bisphosphonates have been linked to a side effect known as Osteonecrosis of the Jaw (ONJ). Also known as Dead Jaw Syndrome, ONJ is a...

First Fosamax Trial Starts Today

Aug 11, 2009 | Parker Waichman Alonso LLP
The  first  of  hundreds of  Fosamax jaw damage lawsuits is scheduled to go to trial today in a Manhattan federal courtroom. According to Bloomberg.com, the Fosamax lawsuit is the first of  three so-called bellwether cases, the outcomes of which may determine if there will be out-of-court settlements in other cases.Fosamax is one of a number of drugs used to treat osteoporosis known as bisphosphonates.  Other drugs in this class include Actonel, Actonel+Ca, Aredia,...

Fosamax, Other Osteoporosis Drugs Linked to Cancer

Jan 2, 2009 | Parker Waichman Alonso LLP
Popular drugs used to treat osteoporosis may be linked to a risk of esophageal cancer according to the U.S. Food and Drug Administration (FDA).  Reuters is reporting that Merck’s Fosamax (generically known as alendronate)  may be among the bone drugs that carry such a risk.  About 10 million Americans—the vast majority of whom are female—suffer from osteoporosis, said Reuters.Reuters reports that Diane Wysowski of the FDA's drug risk assessment division advised...

More Fosamax News